- Home
- HRMY vs HTH Comparison
HRMY vs HTH Comparison
Compare HRMY & HTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- HTH
- Stock Information
- Founded
- HRMY 2017
- HTH 1998
- Country
- HRMY United States
- HTH United States
- Employees
- HRMY N/A
- HTH N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- HTH Major Banks
- Sector
- HRMY Health Care
- HTH Finance
- Exchange
- HRMY Nasdaq
- HTH Nasdaq
- Market Cap
- HRMY 1.8B
- HTH 1.9B
- IPO Year
- HRMY 2020
- HTH 2004
- Fundamental
- Price
- HRMY $34.00
- HTH $30.77
- Analyst Decision
- HRMY Strong Buy
- HTH Hold
- Analyst Count
- HRMY 9
- HTH 2
- Target Price
- HRMY $54.44
- HTH $33.00
- AVG Volume (30 Days)
- HRMY 642.5K
- HTH 468.9K
- Earning Date
- HRMY 08-05-2025
- HTH 07-24-2025
- Dividend Yield
- HRMY N/A
- HTH 2.33%
- EPS Growth
- HRMY 13.13
- HTH 15.07
- EPS
- HRMY 2.62
- HTH 1.97
- Revenue
- HRMY $744,852,000.00
- HTH $1,208,822,000.00
- Revenue This Year
- HRMY $20.10
- HTH N/A
- Revenue Next Year
- HRMY $18.01
- HTH $1.36
- P/E Ratio
- HRMY $13.10
- HTH $15.71
- Revenue Growth
- HRMY 20.62
- HTH 2.13
- 52 Week Low
- HRMY $26.47
- HTH $26.67
- 52 Week High
- HRMY $41.61
- HTH $35.32
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- HTH 52.06
- Support Level
- HRMY $31.70
- HTH $30.92
- Resistance Level
- HRMY $35.08
- HTH $32.16
- Average True Range (ATR)
- HRMY 0.95
- HTH 0.53
- MACD
- HRMY 0.27
- HTH 0.04
- Stochastic Oscillator
- HRMY 71.80
- HTH 50.34
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.